Journal of Dermatology最新文献

{"title":"Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis","authors":"Qin-Xiao Wang,&nbsp;Hai-Yang He,&nbsp;Ying-Luo Niu,&nbsp;Sheng Fang","doi":"10.1111/1346-8138.17869","DOIUrl":"https://doi.org/10.1111/1346-8138.17869","url":null,"abstract":"<div>\u0000 \u0000 <p>Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic. Disease severity was assessed using body surface area (BSA), Peak Pruritus Numerical Rating Scale (PP-NRS), and Investigator Global Assessment (IGA) scores. Significant improvements were observed in BSA (<i>p</i> &lt; 0.05), PP-NRS (<i>p</i> &lt; 0.001), and IGA (<i>p</i> &lt; 0.01) at week 4. Treatment was well tolerated, with no serious adverse events leading to discontinuation. The findings of this study suggest that tofacitinib could be an appealing approach for treating PLCA. Further large-scale, randomized controlled trials are necessary to confirm its long-term efficacy and safety.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1461-1464"},"PeriodicalIF":2.7,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Venous Thromboembolism (VTE) in Patients With Autoimmune Bullous Diseases: Insights From Recent VTE Guidelines","authors":"Maho Kawamoto,&nbsp;Takashi Sakai,&nbsp;Ryo Nishiyori,&nbsp;Yutaka Hatano","doi":"10.1111/1346-8138.17876","DOIUrl":"https://doi.org/10.1111/1346-8138.17876","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1475-1477"},"PeriodicalIF":2.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study","authors":"Yaping Huang,&nbsp;Chengjie Ke,&nbsp;Maohua Chen","doi":"10.1111/1346-8138.17886","DOIUrl":"10.1111/1346-8138.17886","url":null,"abstract":"<div>\u0000 \u0000 <p>Ritlecitinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe alopecia areata in adults and adolescents 12 years and older, which has become a promising treatment. Given their widespread clinical use, a comprehensive real-world study of their adverse events (AEs) is warranted. This study aims to offer insights into the characteristics of ritlecitinib's association with AEs. Disproportionality metrics, including the reporting odds ratio, proportional reporting ratio, information component, and empirical Bayesian geometric mean, were employed in our study. AE signals are determined by using these algorithms. The database for analysis, sourced from the FDA Adverse Event Reporting System (FAERS), covers the period from the first quarter of 2023 to the fourth quarter of 2024. A total of 12 390 AEs were identified, with 18 positive signal PTs in our study. The common AEs comprised headache (<i>n</i> = 39, ROR 3.22), blood creatine phosphokinase increased (<i>n</i> = 24, ROR 57.42), urticaria (<i>n</i> = 21, ROR 6.02), acne (<i>n</i> = 15, ROR 13.13), infection (<i>n</i> = 13, ROR 3.51), drug hypersensitivity (<i>n</i> = 13, ROR 3.49), among other AEs. Notably, five new and unexpected significant AEs that were off-label were also found, including diabetes mellitus, hair color changes, thyroid disorder, blood cholesterol abnormality, and increased lipids. Our study could provide a comprehensive safety overview of ritlecitinib during patient treatment and guide its clinical practice.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1561-1569"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics","authors":"Koji Kamiya,&nbsp;Yukari Okubo,&nbsp;Yayoi Tada,&nbsp;Hidehisa Saeki,&nbsp;Yukie Yamaguchi,&nbsp;Akimichi Morita,&nbsp;Masatoshi Abe,&nbsp;Masanari Kodera,&nbsp;Shigetoshi Sano,&nbsp;Mamitaro Ohtsuki","doi":"10.1111/1346-8138.17871","DOIUrl":"10.1111/1346-8138.17871","url":null,"abstract":"<div>\u0000 \u0000 <p>The introduction of biological agents has significantly improved therapeutic outcomes for patients with psoriasis. However, the long-term use of biologics may present substantial burdens for patients due to various factors. Therefore, identifying effective maintenance therapy is important to reduce treatment burden while maintaining disease control. We conducted a questionnaire-based study to assess patient satisfaction, quality of life, and concerns with ongoing biologic therapy, an oral treatment, as maintenance therapy in psoriasis vulgaris patients in remission. We first surveyed patient-reported outcomes, including treatment satisfaction, quality of life, and concerns with ongoing biologic therapy. Between December 2020 and June 2022, a total of 209 patients with psoriasis vulgaris, including those with joint symptoms, were enrolled. The mean Psoriasis Area and Severity Index score was 0.30, and the mean Dermatology Life Quality Index score was 0.25, confirming that patients remained in remission. The majority of patients (96.1%) reported overall satisfaction with biologic therapy, while 98.6% were satisfied with the therapeutic efficacy. However, 18.2% of patients reported pain, distress, or anxiety related to injection administration, 8.2% expressed concerns regarding treatment safety, and 38.0% reported dissatisfaction with the financial burden of biologic therapy. While patient satisfaction with the therapeutic effects of biologic agents was high, concerns regarding treatment cost and uncertainty about the duration of therapy remained prominent. These findings underscore the need for alternative maintenance strategies, such as oral therapies, to optimize long-term disease management and improve patient adherence and quality of life. Although this questionnaire-based analysis did not include the administration of oral therapies such as apremilast, it provides insights that may support future consideration of oral maintenance treatments for patients with psoriasis.</p>\u0000 <p><b>Trial Registration:</b> Japan Registry of Clinical Trials: jRCTs031200238</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1545-1554"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PTEN Hamartoma Tumor Syndrome/Cowden Syndrome With Diffuse Sebaceous Gland Hyperplasia: Description of an Atypical Phenotype and a Previously Undescribed Pathogenic Variant","authors":"Alberto Soto-Moreno,&nbsp;María Olivares-Guerrero,&nbsp;David López-Delgado,&nbsp;Salvador Arias-Santiago","doi":"10.1111/1346-8138.17880","DOIUrl":"10.1111/1346-8138.17880","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e923-e924"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Infantile Hemangiomas in Male and Female Infants: A Prospective Study","authors":"Kaizhi Zhang,&nbsp;Tong Qiu,&nbsp;Jiangyuan Zhou,&nbsp;Xue Gong,&nbsp;Yuru Lan,&nbsp;Zixin Zhang,&nbsp;Yi Ji","doi":"10.1111/1346-8138.17885","DOIUrl":"10.1111/1346-8138.17885","url":null,"abstract":"<div>\u0000 \u0000 <p>Infantile hemangioma (IH) predominantly occurs in females, yet few studies have compared the clinical characteristics of IH between girls and boys. This study compared the clinical characteristics of females and males with IH. This prospective study included 1016 patients with IHs for whom complete clinical data were available. A total of 701 female and 315 male patients with IH were enrolled in this study. Male patients presented a high incidence of superficial IH (73.97% in boys vs. 68.62% in girls, <i>p</i> = 0.084) and localized IH (90.48% in boys vs. 81.60% in girls, <i>p</i> &lt; 0.001), whereas female patients were more likely to have segmental IH (11.41% in girls vs. 5.08% in boys, <i>p</i> = 0.001). The incidence of IH rebound after oral propranolol was somewhat more likely to occur in females than in males (11.86% vs. 5.15%, <i>p</i> = 0.063). For superficial IH, ulcers developed in 4.78% of female patients compared with 1.72% of male patients (<i>p</i> = 0.044). In this prospective study, we identified new sex differences in the clinical characteristics of IH. Localized and superficial IHs were more common in males. Females were more prone to developing ulcers in superficial IHs and experiencing IH rebound after treatment with propranolol.</p>\u0000 <p><b>Trial Registration:</b> Clinicaltrials.gov identifier: NCT03331744</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1555-1560"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Extramammary Paget Disease 2025","authors":"Shigeto Matsushita,&nbsp;Ikko Kajihara,&nbsp;Keita Tsutsui,&nbsp;Ikuko Hirai,&nbsp;Takeo Maekawa,&nbsp;Takuya Maeda,&nbsp;Kae Okuma,&nbsp;Toshihiro Kimura,&nbsp;Takaya Komori,&nbsp;Sayuri Sato,&nbsp;Takayuki Fusumae,&nbsp;Tatsuhiko Mori,&nbsp;Tatsuo Maeda,&nbsp;Hiroshi Uchi,&nbsp;Hiroshi Koga,&nbsp;Tomomitsu Miyagaki,&nbsp;Yasuhiro Nakamura","doi":"10.1111/1346-8138.17855","DOIUrl":"10.1111/1346-8138.17855","url":null,"abstract":"<p>Extramammary Paget disease (EMPD) is a rare malignancy that primarily arises in apocrine gland-bearing areas such as the genital, perianal, and axillary regions. The clinical and biological heterogeneity of EMPD, together with a lack of evidence from large-scale studies, has made it difficult to establish standardized approaches to diagnosis and treatment. To address these issues, the 2025 Japanese Guidelines for the Management of EMPD were developed, providing evidence-based recommendations tailored to the healthcare context in Japan. These guidelines were constructed using the Minds Guideline Development Manual 2020 (ver. 3.0), adhering to systematic review principles and incorporating both Japan and international research findings. A multidisciplinary panel of dermatologists, oncologists, surgeons, and other specialists developed the guidelines through a consensus-based process, which included structured discussions and grading of evidence. The primary focus of this condensed version is on six critical clinical questions, which address key aspects of EMPD management, including the role of mapping biopsy in diagnosis, the use of sentinel lymph node biopsy in cases of suspected dermal invasion, the efficacy of nonsurgical therapies when surgery is not an option, the efficacy of lymph node dissection for multiple regional lymph node metastases, the efficacy of radiation therapy after regional lymph node dissection, and systemic treatment options for advanced disease. The recommendations aim to improve diagnostic accuracy, optimize therapeutic approaches, and support clinical decision-making by providing a clear framework for the management of EMPD. By focusing on these critical areas, the guidelines strive to enhance patient outcomes and contribute to the advancement of evidence-based care for this rare and challenging malignancy.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"e795-e814"},"PeriodicalIF":2.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17855","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Secondary Syphilis Mimicking a Malignant Lymphoma","authors":"Arisa Kimura,&nbsp;Naohito Hatta,&nbsp;Takayuki Ishii","doi":"10.1111/1346-8138.17883","DOIUrl":"10.1111/1346-8138.17883","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e929-e930"},"PeriodicalIF":2.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Metastatic Pigmented Basal Cell Carcinoma With Low Tumor Mutation Burden Responding to Nivolumab","authors":"Yurie Matsuzaki,&nbsp;Jiro Uehara,&nbsp;Tomoki Shibahara,&nbsp;Kaito Suzuki,&nbsp;Koji Yoshino","doi":"10.1111/1346-8138.17881","DOIUrl":"10.1111/1346-8138.17881","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e925-e926"},"PeriodicalIF":2.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of Biologics and Small Molecule Drugs in the Treatment of Hidradenitis Suppurativa","authors":"Shumeng Xue,&nbsp;Yanyan He,&nbsp;Lu Pei,&nbsp;Haoxiang Xu","doi":"10.1111/1346-8138.17874","DOIUrl":"10.1111/1346-8138.17874","url":null,"abstract":"<div>\u0000 \u0000 <p>Hidradenitis suppurativa (HS) is a chronic, debilitating, inflammatory skin disease that is challenging to treat. In recent years, biologic therapies and small-molecule drugs have been used to improve the treatment landscape of moderate-to-severe HS. Biologics, including anti-tumor necrosis factor-α agents and interleukin inhibitors, target specific cytokines or cell-surface receptors involved in the immunopathogenesis of HS. These therapies have shown efficacy in reducing inflammation, pain, and the formation of abscesses and fistulas, as well as in improving patients' quality of life. Small-molecule drugs offer advantages such as oral administration, potentially different mechanisms of action, targeting of intracellular signaling pathways, and modulation of the immune response. Recent studies have focused on optimizing the use of these drugs, understanding their long-term effects, and exploring combination therapies. This review summarizes progress in the application of biologics and small-molecule drugs for the treatment of HS.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1337-1350"},"PeriodicalIF":2.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}